Casimersen clinical trials
Also written SRP-4045 and AMONDYS 45.
How each study uses casimersen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 25 Feb 2021 · AMONDYS 45 · NDA 213026 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Sarepta Therapeutics, Inc. (3) · Kevin Flanigan (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses casimersen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)CompletedPhase 3Sarepta Therapeutics, Inc.NCT02500381Written as SRP-4045
- An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyTerminatedPhase 3Sarepta Therapeutics, Inc.NCT03532542Written as Casimersen
- A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.CompletedPhase 2Kevin FlaniganNCT04179409Written as Amondys 45
- Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) PatientsCompletedPhase 1Sarepta Therapeutics, Inc.NCT02530905Written as SRP-4045
Codes
What other systems call casimersen · ClinicalTrials.gg INT001650
- MeSH (NLM) C000718147casimersenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) X8UHF7SX0RCASIMERSENConfirmed FDA, NLM, Wikidata
- RxNorm 2480096One source FDA
- Wikidata Q105714904casimersenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169830CasimersenOne source FDA
- DrugBank DB14984One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718147 | casimersen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | X8UHF7SX0R | CASIMERSEN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2480096 | — | One source FDA |
| Wikidata | Q105714904 | casimersen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169830 | Casimersen | One source FDA |
| DrugBank | DB14984 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.